$LCTX

$1.00 -$0.00 (0.31%) Close

$LCTX Overview Financial Statements SEC Filings Executives News Red Flags Capital Raising Ownership Insider Transactions Congressional Trades

Ownership

13F as of Q2 2026 · 252.9M shares outstanding

Who owns LCTX?

By type of holder

Institutions 44.0% Insiders 33.1% Everyone else 22.9%

Concentration Top 10 holders own 82.2%

Neal C. Bradsher 22.9% · Broadwood Partners, L.P. 22.7%

Institutional ownership

44.0%

-0.2 pts vs last qtr

Institutional holders

127

-2 vs last qtr

Net shares bought

−436.6K

by institutions in Q2 2026

New / sold out

35 / 37

positions opened vs closed

How is ownership changing?

Institutions, last 8 quarters

Biggest buyers in Q2 2026

BlackRock, Inc. +9.3M
Geode Capital Management, LLC +2.8M

Biggest sellers in Q2 2026

Raffles Associates LP SOLD OUT −5.4M
Armistice Capital, LLC SOLD OUT −3.2M

Who is planning to sell?

No insider has filed a notice of proposed sale (Form 144) for Lineage Cell Therapeutics Inc in the last 12 months.

Is your stake being diluted?

Diluted share count, FY2014–FY2025

+246.2%

+19.41% a year

Each share's claim on the business

−71.1%

shrank without buying or selling a share

Spent on buybacks vs paid in stock

— vs $46.1M

over 8 fiscal years

Diluted shares, split-adjusted

Buybacks Stock-based comp

How patient are the owners?

Institutional shares by how long they've been held

5+ years80% 3–5 years2% 1–3 years4% Under 1 year14%

Quarterly turnover

18.7%

of institutional shares changed hands

Top 10 managers, median time held

5 years

Super Investors

Investment managers reporting LCTX on Form 13F

Holder	Shares	% of company	Change vs last qtr	Held since	% of their book
BC Broadwood Capital Inc 13D · 23.0%	49.6M	19.60%	Unchanged	≤2021	3.4%
Shares held by quarter Peak holding49.6M (Q1'25) Change over 8 quarters+7.9M Share of the company19.600% Disclosed stake13D · 23.0% Broadwood Capital Inc's full portfolio →
B BlackRock, Inc.	13.2M	5.21%	+9.3M (+241.2%)	≤2021	0.0%
Shares held by quarter Peak holding13.2M (Q2'26) Change over 8 quarters+3.3M Share of the company5.210% BlackRock, Inc.'s full portfolio →

Broadwood Capital Inc

13D · 23.0%

49.6M

% of company

19.60%

Change vs last qtr

Unchanged

Held since

≤2021

BlackRock, Inc.

13.2M

% of company

5.21%

Change vs last qtr

+9.3M (+241.2%)

Held since

≤2021

28 more super investors behind a free account

See every manager holding Lineage Cell Therapeutics Inc, how their position has changed, and how long they've held it.

Institutional Funds

Mutual funds and ETFs reporting LCTX on Form N-PORT; together they hold 9.3% of the company

Fund	Position value	Shares	% of company	% of the fund	As of
VT Vanguard Total Stock Market Index Fund Vanguard Index Funds	$7.74M	5.9M	2.34%	0.00%	June 30, 2026
IR iShares Russell 2000 ETF iShares Trust	$5.45M	4.2M	1.64%	0.01%	June 30, 2026

Vanguard Total Stock Market Index Fund

Vanguard Index Funds

Position value

$7.74M

% of company

2.34%

% of the fund

0.00%

As of

June 30, 2026

iShares Russell 2000 ETF

iShares Trust

Position value

$5.45M

% of company

1.64%

% of the fund

0.01%

As of

June 30, 2026

23 more funds behind a free account

See every fund holding Lineage Cell Therapeutics Inc and how much of the fund the position is.

Insiders and 5%+ holders

From Forms 3/4/5 and Schedules 13D/G

Holder	Shares	% of company	Change vs last qtr	8 quarters	Held since	% of their book
NC Neal C. Bradsher 5%+ holder 13D · 23.1%	57.8M	22.87%	—	—	—	—
This holder reports through Schedule 13D/G, not a quarterly 13F. Share of the company22.870% Disclosed stake13D · 23.1% View the 13D/G filing →
BP Broadwood Partners, L.P. 5%+ holder 13D · 23.0%	57.5M	22.72%	—	—	—	—
This holder reports through Schedule 13D/G, not a quarterly 13F. Share of the company22.720% Disclosed stake13D · 23.0% View the 13D/G filing →

Neal C. Bradsher

5%+ holder13D · 23.1%

57.8M

% of company

22.87%

Change vs last qtr

—

Held since

—

Broadwood Partners, L.P.

5%+ holder13D · 23.0%

57.5M

% of company

22.72%

Change vs last qtr

—

Held since

—

4 more holders behind a free account

See every insider and 5%+ holder of Lineage Cell Therapeutics Inc.

Comments